Galderma R&D Adopts Agilent Technologies’ Electronic Lab Notebook
SANTA CLARA, Calif. and SOPHIA ANTIPOLIS, France, Feb. 1, 2010
Agilent Technologies, Inc. (NYSE: A) and Galderma R&D today announced that Galderma has adopted the Agilent Electronic Lab Notebook (ELN) to automate scientific data management at its main R&D center, the largest facility of its type devoted to dermatological research and development.
“We involved our end users in demonstration sessions based on our workflow for chemistry,” said Catherine Parigot, project leader, Information Management Department, Galderma R&D in Sophia-Antipolis. After comparison with the leading solutions on the market, the user choice of Agilent ELN was unanimous. This was based largely on the ergonomics of the interface and the intuitive navigation through the different functions. Agilent was also able to demonstrate integration with existing information systems, such as our SDMS and our molecular registration system.”
“Electronic lab notebook systems is a very competitive category and we are extremely pleased that the Galderma team recognized the efficiencies, ease-of-use and high-level of support of the Agilent ELN,” said Debra Toburen, Agilent senior product manager, Informatics. “This is just the latest example of the rapid growth of the Agilent ELN product line.”
The Agilent ELN provides numerous benefits beyond eliminating paper lab notebooks. The open architecture is designed to simplify and accelerate the R&D process by streamlining data capture, speeding data search and retrieval, and eliminating redundant data entry. The system facilitates cross-team collaboration and easily integrates with existing processes and procedures. Agilent ELN contains safeguards for intellectual property and maintains record traceability.
“The use of the intrinsic Analytical Request Module (ARM) to manage our analytical workflow will enable us to replace our existing LIMS application,” Parigot added. “The scope of this initial project will therefore provide an ELN to our chemists and our analysts and trace all the interactions between these two groups.”
About Galderma
Galderma, created in 1981 as a joint venture between Nestl� and L’Or�al, is a global leading pharmaceutical company specializing in the research, development and marketing of therapeutic, corrective and aesthetic solutions in dermatology. Its expertise covers a broad spectrum of skin, hair and nail diseases.
The company, headed by President and CEO Humberto C. Antunes, has whollyowned affiliates in 31 countries but is selling its products in 65 countries thru a worldwide network of exclusive sales agents. Galderma is committed to improving the health of skin with an extensive line of products that treat a range of dermatological conditions including: acne, rosacea, fungal nail infections (onychomycosis), psoriasis and steroid-responsive dermatoses, pigmentary disorders, medical solutions for skin senescence and skin cancers. With its research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities dedicated exclusively to dermatology. Leading dermatology brands include Differin®, MetroGel® 1%/Rozex®, Clobex®, Tri-Luma®, Loceryl® and Cetaphil®. Recently launched products include Pliaglis(tm), a topical anaesthetic for dermatologic procedures in the United States; Epiduo®, an innovative combination product for the treatment of acne in Europe and Argentina; and an injectable neuromodulator for the correction of wrinkles, called Dysport® in Brazil and Argentina, and Azzalure® in Europe. The Company’s website is www.galderma.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company’s 17,000 employees serve customers in more than 110 countries. Agilent had net revenues of $4.5 billion in fiscal 2009. Information about Agilent is available on the Web at www.agilent.com.
